AU2013204533A1 — Crystalline forms
Assigned to AstraZeneca AB · Expires 2013-10-31 · 13y expired
What this patent protects
The present invention discloses certain new solid state forms of (S)-4-amino-N-(1 (4-chlorophenyl)-3-hydroxypropyl)- 1-(71-I-pyrrolo[2,3 -d]pyrimidin-4-yl)piperidine-4 s carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of s…
USPTO Abstract
The present invention discloses certain new solid state forms of (S)-4-amino-N-(1 (4-chlorophenyl)-3-hydroxypropyl)- 1-(71-I-pyrrolo[2,3 -d]pyrimidin-4-yl)piperidine-4 s carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.